#ai-bio

Autonomous labs run by GPT‑6 Astra could speed breakthroughs in biology, chemistry and materials science—yet raise safety, cost and alignment concerns.

AI rapidly reshapes medicine—clinically tested AI now outperforms doctors in ERs, discovers new drugs, and sparks a debate on cost, workforce, and ethics.

Engram’s 2.6 B‑parameter LLM uses a 4.3 B Engram table and SVD‑compressed layers to deliver richer historical and philosophical completions after 100 M tokens—see how small‑scale models are reshaping AI cost and performance.

Anthropic’s Claude AI uncovers a novel enzyme system in phage DNA, mirroring CRISPR‑like repeats, showing how AI‑driven research can accelerate biotech discoveries.

Jensen Huang claims AI won’t pose an existential risk by 2030, sparking debate over corporate bias and the true safety of advanced AI.

Explore how transhumanist theory shifts the AI debate from “Humans vs. AI” to human‑technology integration and the challenges that may delay the rise of Homo Evolutis.

DeepMind’s new AI focus on decoding DNA’s regulatory “switches” could transform genomics, raise ethical questions on identity, and spark debate on future bio‑research.

Obama urges federal AI regulation to curb misuse, warning that powerful models could enable biological threats and financial chaos, and calls for bipartisan policy action.

Groundbreaking CAR T cell therapy may have cured a 3‑year‑old’s liver cancer in an outpatient setting, but real‑world data are still unverified—read the latest AI‑driven insights and access challenges.

Explore how AI sparks both productivity gains and existential risks, from bio‑security threats to market hype and upcoming model releases.